2012 EDUCATIONAL BOOK - American Society of Clinical Oncology

28. Khouri IF, Przepiorka D, van Besien K, et al. Allogeneic blood or
marrow transplantation for chronic lymphocytic leukaemia: timing of transplantation
and potential effect of fludarabine on acute graft-versus-host
disease. Br J Haematol. 1997;97:466-473.
29. Sorror ML, Storer BE, Sandmaier BM, et al. Five-year follow-up of
patients with advanced chronic lymphocytic leukemia treated with allogeneic
hematopoietic cell transplantation after nonmyeloablative conditioning.
J Clin Oncol. 2008;26:4912-4920.
30. Dreger P, Brand R, Hansz J, et al. Treatment-related mortality and
graft-versus-leukemia activity after allogeneic stem cell transplantation for
chronic lymphocytic leukemia using intensity-reduced conditioning. Leukemia.
2003;17:841-848.
31. Brown JR, Kim HT, Li S, et al. Predictors of improved progression-free
survival after nonmyeloablative allogeneic stem cell transplantation for
advanced chronic lymphocytic leukemia. Biol Blood Marrow Transplant.
2006;12:1056-1064.
32. Delgado J, Thomson K, Russell N, et al. Results of alemtuzumab-based
reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia:
a British Society of Blood and Marrow Transplantation Study. Blood.
2006;107:1724-1730.
33. Khouri IF. Reduced-intensity regimens in allogeneic stem-cell transplantation
for non-hodgkin lymphoma and chronic lymphocytic leukemia.
Hematology Am Soc Hematol Educ Program. 2006:390-397.
34. Schetelig J, Thiede C, Bornhauser M, et al. Evidence of a graft-versusleukemia
effect in chronic lymphocytic leukemia after reduced-intensity
404
JOHN G. GRIBBEN
conditioning and allogeneic stem-cell transplantation: the Cooperative German
Transplant Study Group. J Clin Oncol. 2003;21:2747-2753.
35. Moreno C, Villamor N, Colomer D, et al. Clinical significance of
minimal residual disease, as assessed by different techniques, after stem cell
transplantation for chronic lymphocytic leukemia. Blood. 2006;107:4563-4569.
36. Dreger P, Brand R, Milligan D, et al. Reduced-intensity conditioning
lowers treatment-related mortality of allogeneic stem cell transplantation
for chronic lymphocytic leukemia: a population-matched analysis. Leukemia.
2005;19:1029-1033.
37. Schetelig J, van Biezen A, Brand R, et al. Allogeneic hematopoietic
stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion:
a retrospective European Group for Blood and Marrow Transplantation
analysis. J Clin Oncol. 2008;26:5094-5100.
38. Dreger P, Corradini P, Kimby E, et al. Indications for allogeneic stem
cell transplantation in chronic lymphocytic leukemia: the EBMT transplant
consensus. Leukemia. 2007;21:12-17.
39. Montserrat E, Moreno C, Esteve J, et al. How I treat refractory CLL.
Blood. 2006;107:1276-1283.
40. Tsimberidou AM, Keating MJ. Treatment of fludarabine-refractory
chronic lymphocytic leukemia. Cancer. 2009;115:2824-2836.
41. Oscier D, Wade R, Davis Z, et al. Prognostic factors identified three risk
groups in the LRF CLL4 trial, independent of treatment allocation. Haematologica.
2010;95:1705-1712.
42. Ramsay AG, Johnson AJ, Lee AM, et al. Chronic lymphocytic leukemia
T cells show impaired immunological synapse formation that can be reversed
with an immunomodulating drug. J Clin Invest. 2008;118:2427-2437.